Understanding and improving treatment for heparin-induced thrombocytopenia
Official title: New approaches to the pathophysiology, diagnosis and management of heparin-induced thrombocytopenia
Funded at Mayo Clinic Rochester · NIH-10901956 · Data updated 2026-11-12
This study is looking at a condition called heparin-induced thrombocytopenia (HIT) to help doctors tell the difference between harmful and harmless antibodies, so they can make better treatment choices and avoid giving patients unnecessary medications that might cause more bleeding.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 15, 2021 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $397,500 |
| NIH project number | 5R01HL158932-04 |
| Project ID | NIH-10901956 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with heparin-induced thrombocytopenia who are experiencing complications related to their condition.
✕Less likely to help
Patients who do not have heparin-induced thrombocytopenia or those who are not receiving anticoagulant therapy may not benefit from this research.
What this research studies
This research investigates heparin-induced thrombocytopenia (HIT), a serious condition where antibodies cause a dangerous drop in platelet levels. The team aims to differentiate between harmful and harmless antibodies that affect treatment decisions, which can lead to unnecessary use of alternative anticoagulants that may cause more bleeding. By isolating and characterizing these antibodies from patient samples, the researchers will develop new monoclonal antibodies and test their effects in a mouse model. This approach seeks to enhance diagnostic accuracy and treatment options for patients suffering from HIT.
Why it matters
Potential benefit: If successful, this research could lead to better diagnosis and safer treatment options for patients with heparin-induced thrombocytopenia.
How similar studies have gone: Previous research has shown promise in understanding antibody behavior in HIT, but this approach aims to provide novel insights and improvements in treatment.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Padmanabhan, Anand — Mayo Clinic Rochester
- Study coordinator: Padmanabhan, Anand
Related research
Other NIH-funded projects on the same topics.
-
New ideas to understand, diagnose, and treat heparin-induced thrombocytopenia
A Mayo Clinic led study will look at the different kinds of HIT antibodies to improve diagnosis and treatment for people with HIT.
-
Second-generation BLVRB inhibitors to help chemotherapy patients with low platelets
A new drug candidate is being developed to raise platelet counts in patients whose cancer treatment lowers them, reducing bleeding risk.
-
Immunobiology of vaccine-related clotting after adenovirus vaccines
This research asks how antibodies linked to a rare vaccine-related clotting condition (VITT) interact with specific blood proteins to cause clots after certain COVID-19 vaccines.
-
Understanding and diagnosing Heparin-Induced Thrombocytopenia (HIT)
A project to understand the immune factors behind HIT and develop faster, more accurate tests to help people who need heparin therapy.
-
Fetal and neonatal platelet allergy: understanding why some babies bleed
A study to understand why maternal antibodies cause serious bleeding in babies with FNAIT, using an animal model and human-relevant clues to improve future care for affected families.
-
Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine
This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.